Salmonella as a Vaccine Vector for Influenza Virus  by Van, Thi Thu Hao et al.
 Procedia in Vaccinology  7 ( 2013 )  23 – 27 
1877-282X © 2013 The Authors. Published by Elsevier B.V. 
Selection and peer-review under responsibility of the 6th Vaccine Conference Organizing Committee.
doi: 10.1016/j.provac.2013.06.005 
6th Vaccine & ISV Congress, Shanghai 2012 
Salmonella as a vaccine vector for influenza virus 
 
Thi Thu Hao Vana,c, Yu-Chen Lina, Thi Nhu Ngoc Vanb, Thi Quy Nguyenb, Thi Thu Hong 
Leb, Thi Huyen Dob, Nam Hai Truongb, Peter J. Coloea and Peter M. Smookera 
aSchool of Applied Sciences, RMIT University, Australia 
bInstitute of Biotechnology (IBT), Vietnam Academy of Science and Technology (VAST), Hanoi, Vietnam. 
cCorresponding author    
Abstract 
Salmonella have many advantages as a vaccine delivery vector, they are easy to produce, easy to administer (orally), and able to elicit 
humoral immunity which induces serum and secretory IgA antibody. In addition, they induce robust cell-mediated immune responses 
such as cytotoxic and memory T lymphocytes. Moreover, when Salmonella is being used as a vaccine vector, immune responses 
against both Salmonella and the heterologous antigen will be induced, providing protection against infection by Salmonella and the 
heterologous pathogen. In this study, Salmonella STM-1, an attenuated strain which was developed at RMIT and licensed for the 
prevention of salmonellosis in poultry, is used as a delivery vector for an influenza antigen. Different strategies are used to display 
the influenza hemagglutinin (HA) antigen in various destinations to optimise protein expression and immunogenicity. Comparing the 
immune responses in a mouse trial, mice which were vaccinated with Salmonella to express the HA protein inside cell (under the 
control of the starvation induced S. enterica sspA promoter) did not show robust T cell and humoral responses in comparison to mice 
vaccinated with HA protein expressed in yeast. Therefore other systems are being engineered, including one to display the HA 
antigen on the outer membrane of Salmonella and another to secrete it into the media. Directing heterologous antigen for surface 
display or secretion may increase humoral responses. Expression of HA protein in these systems was detected by western blot 
analysis. An animal trial is underway to examine the immunogenicity of these promising systems. 
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1. Introduction 
contagious and can results in severe respiratory illness in humans and animals. There were several global influenza 
pandemics in the past century, such as H1N1 Spanish flu in 1918, H2N2 Asian in 1957 and H3N2 Hong Kong in 1968, 
which have killed 50 to 100 million people worldwide [1]. More recently, the evolution of the highly pathogenic avian 
H5N1 and swine-origin H1N1 influenza virus in 2009, has underlined the continued threat of influenza viruses on a 
global scale. The rapid antigenic-variation makes the eradication of influenza virus difficult to be accomplished [2]. The 
development of human-transmissible H5N1 virus would cause a pandemic, hence stringent precautions should be 
undertaken [3, 4]. The best prevention measure for influenza virus infections is through vaccination [5]. 
Live attenuated bacteria as a vaccine and vector offer many advantages compared with other type of vaccines. Live 
attenuated strains can be delivered by a simple oral mode of inoculation and may confer protection following a single 
dose due to several rounds of replication in the host [6]. In addition, they are economical to develop and can be 
manufactured commercially on a large scale [7]. The use of live oral vaccines also enhances the range of antigens 
presented to the mucosal immune system compared with antigens presented after intramuscular injection of killed 
organisms. The attenuated organisms provide long lasting immunity by eliciting strong cellular responses, including 
CD4+ and CD8+ T lymphocytes [8]. In the last few decades, Salmonella-based live-vaccine vectors have been 
extensively investigated for the prevention of a variety of diseases caused by bacteria, viruses and parasites [9]. 
Different studies have been carried out using different antigen delivery and expression strategies for these Salmonella-
based live-vaccine vectors [10, 11, 12, 13]. In this study, Salmonella enterica serovar Typhimurium STM-1, an 
attenuated strain which was developed at RMIT, harboring a mutation in the aroA gene region that renders it attenuated 
and licensed for the prevention of salmonellosis in poultry [14], is used as a delivery vector for an influenza antigen. 
Different strategies are used to display the influenza hemagglutinin (HA1) antigen in various destinations to optimise 
protein expression and immunogenicity.  
2. Material and methods 
2.1 Cloning and expression of HA1 protein in yeast and in Salmonella STM1 
2.1.1 Cloning and expression of HA1 protein in Pichia pastoris 
 The full length HA encoding gene of H5N1 strain A/Hatay/2004/(H5N1) isolated from Vietnam (GenBank 
accession No AJ867075) was kindly provided by Molecular Microbiology Laboratory, Institute of Biotechnology, 
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Vietnam. The gene without the signal peptide, encoding for mature H5HA1 (HA1 fragment from H5N1 virus) was 
amplified by polymerase chain reaction (PCR). To create a P. pastoris clone expressing H5HA1, this gene was inserted 
into the pPIC9 vector and transformed into P. pastoris SMD1168 by electroporation. A control strain was generated by 
the same protocol using the empty pPIC9 vector. H1HA1 (HA1 fragment from H1N1 A/Puerto Rico/8/34 virus) was 
also created and used as a model antigen, where the HA1 gene isolated from the A/PR/8/34 virus was cloned into 
-A vector, and the construct was transformed into P. pastoris chromosomal DNA. These recombinant proteins 
were secreted into the expression media as soluble proteins, and were purified by Immobilised Metal Affinity 
Chromatography (IMAC). These proteins were used in an animal trial to compare their immunogenictiy with H5HA1 
expressed in Salmonella STM1 as described below. 
2.1.2 Expression of H5HA1 in Salmonella STM1/sspA 
H5HA1 was cloned into pkk223-2 plasmid containing the starvation induced S. enterica sspA promoter [15] and 
transferred into STM1 (called H5HA1STM1/sspA). Protein will be expressed intracellularly under the control of the 
sspA promoter. This Salmonella clone was used to directly deliver the H5HA1 antigen into animals. 
2.2 Animal trial to examine the immune responses 
An animal trial was carried out to evaluate their immunogenicity and suitability as a vaccine candidate. All animal 
experimentation was approved by the RMIT Animal Ethics Committee. Three immunisations were given to each animal 
incomplete adjuvant for the subsequent two injections. 
Serum samples were collected 3 weeks after the final vaccination to analyse the immunological responses against 
the delivered proteins (Western blot, and Enzyme-linked immunosorbent assays (ELISA)). At the end of the trial, 
mouse spleen cells were collected for enzyme-linked immunospot (ELISPOT) assay [14].  
2. 3 Displaying HA1 protein in different destinations to optimise protein expression and immunogenicity  
HA1 protein was displayed on the outer membrane of Salmonella. In addition, HA1 protein was secreted into the 
media using the pMOhly1 plasmid, which encodes the necessary components of the E. coli -haemolysin secretion 
system) [16].  
3. Results and discussions 
The influenza HA glycoprotein specifically binds to cellular receptors consisting of sialic acid. After initiation of 
host cell endocytosis, the HA mediates membrane fusion and viral entry and this protein is the primary target of 
neutralizing antibodies. The HA molecule consists of HA1 and HA2 subunits with the HA1 subunit mediating initial 
contact with the cell membrane and the HA2 fragment responsible for membrane fusion [17]. HA1 known to be the 
major target of neutralizing antibodies that inhibit virus binding to target cells [18, 19]. In this study the recombinant 
HA1 proteins from H5N1 and H1N1 were expressed in yeast and Salmonella was used to deliver H5HA1 where this 
protein was expressed cytoplasmically and the expression and immugenicity of these proteins were evaluated.  
3.1 Expression of HA1 proteins in yeast and in Salmonella STM1/sspA 
The influenza HA glycoprotein H1HA1 and H5HA1 proteins were expressed in yeast and secreted into the media, 
and proteins were visualised as a smear due to glycosylation. Figure 1a shows the expression of H1HA1 protein in yeast 
and this protein was recognised by Anti-A/PR8/34 serum (Figure 1b). In contrast, the HA1 protein was poorly 
expressed in Salmonella when using sspA as a promoter (data not shown). 
3.2 Immune responses of mice vaccinated with H1HA1 and H5HA1 proteins expressed in yeast and H5HA1 expressed 
in Salmonella STM1/sspA 
An animal trial was carried out to vaccinate mice with H1HA1 and H5HA1 proteins and with Salmonella to deliver 
H5HA1 protein. In order to compare the humoral responses mounted against these antigens, ELISA assays were 
performed to test the anti-HA1 IgG responses using sera of infected mice (Figure 2a and 2b). The T cell IL4 and IFN-
responses against proteins and Salmonella-HA1 strains were measured by ELISPOT assay. Results of the ELISPOT 
assays were expressed as the number of spot forming T cells per million splenocytes (SFC) with cells from each mouse 
assayed in duplicate (Figure 3a and 3b).  
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Figure 3a and Figure 3b: ELISPOT assay. Compared to the control groups, mice which were subcutaneously vaccinated with H5HA1
and H1HA1 proteins resulted in significantly increased T cell responses (p<0.05). Mice vaccinated with STM-1 expressing H5HA1
did not show a significantly different T cell response.
Fig. 1a: The silver stained SDS-PAGE gel of H1HA1 protein 
expressed in yeast using Buffered Methanol-Complex
(BMMY) medium.
Lane 1. Protein Marker (P7702, NEB); 2. Clone 1 at time zero; 
3. Clone 1 at 96hrs after expression
Fig. 1b: The Immunoblot with polyclonal anti-PR8/34
(H1N1) antibody.
Lane 1. ColorPlus Prestained Protein Marker (P7709s, NEB);
2. Clone 1 at time zero; 3. Clone 1 at 96hrs after expression 
Fig. 2a and Fig.2b: ELISA assay. Pooled sera from mice vaccinated with H5HA1/yeast elicited strong IgG responses (the endpoint 
titer is 819200, Figure 2a). Mice vaccinated with STM-1 expressing H5HA1 did not show significantly different humoral responses
to the control group (Figure 2b).
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Mice vaccinated with HA1 protein expressed in yeast showed robust T cell and humoral responses, but not mice
vaccinated with Salmonella expressing H5HA1 intracellularly. Pichia has been demonstrated to be a suitable means for 
producing an influenza HA based subunit vaccine [18, 20].
This study focuses on the use of Salmonella as a delivery vector for the HA influenza gene product due to many 
advantages which Salmonella delivery system can offer, such as the low cost and ease of production [10], and it is
particularly suited for vaccination of poultry. In contrast to a study from Terry et al. [15], who demonstrated that sspA
is a useful promoter for single copy expression of heterologous antigens in S. enterica, this study did not result in an
immunogenic H5HA1 vaccine. It has been recommended by Zheng et al that for insoluble antigens such as HA, an 
outer membrane expression strategy is preferable [10]. Therefore, we have obtained two other systems that allow
expression of the influenza protein in STM-1 in other places. These will allow expression either on the surface of STM-
1, or to secrete the protein from the bacterium.
3.3 Different strategies used to display the HA1 antigen in various destinations to optimise protein expression
and immunogenicity.
The HA1 protein was expressed from a vector designed to display protein on the outer membrane of Salmonella.
Figure 4 shows this protein was recognized by an anti-His antibody. The same results were obtained when using anti 
A/PR8/34 serum in the western blot (data not shown).
                
The HA1 protein was also secreted into the media using pMOhly1 plasmid. As can be seen from Figure 5a and 5b, 
HA1 protein was secreted into the media and can be detected after silver staining of sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gels and this protein was recognised by anti-A/PR8/34 serum.
                               
Fig. 5a                                                                                     Fig. 5b
Silver staining SDS-PAGE gel of HA1-pMOhly/STM-1 samples after IMAC purification (Fig. 5a) and western blot using anti 
A/PR8/34 serum (Fig. 5b)
Lanes: 1: STM1 without plasmid; 2: Marker; 3-5: HA1 Salmonella STM-1/pMOhly fractions 1-3 respectively.
Fig. 4: Western blot with anti-His antibody (whole cell lysates, 1 mM IPTG)
Lanes: 1. STM1 without plasmid; 2. Marker (Biorad, 161-0374); 3-8. Clone, induced for 0,1,2,3,4,5 hrs respectively.
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In a recent study by Zheng et al 2012, several strategies were used to examine the immune response to recombinant 
Salmonella-HA proteins, where HA was expressed in either the cytoplasm or in the outer membrane [10]. It has been 
found that the latter strategy induced better B cell and T cell responses than the former strategy. Similarity, when using 
Salmonella strains that expressed the HIV rgp120 antigen, the surface-expressed rgp120 was significantly more 
immunogenic in both the mucosal and systemic compartments than cytoplasmic rgp120 [21]. In our study, HA1 
proteins were targeted to the cell surface (outer membrane) of Salmonella and also secreted into the media. As 
demonstrated above, expression of HA1 protein in these systems was detected by western blot analysis. Both of these 
strategies should allow efficient induction of humoral immunity, as the antigen will be available to interact with the 
specific cells (B cells) that when activated produce antibody. The immunogenicity of these promising systems will be 
evaluated in subsequent vaccination trials. 
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